New York, NY, June 24, 2015 - The results of a study assessing safety and efficacy of sTMS therapy with the NEST® device in adult patients with Major Depressive Disorder (MDD) have been published in the Elsevier journal Brain Stimulation and are now available online on Science Direct.
In the study, over 200 subjects were analyzed across 17 leading academic and private psychiatric institutions in the United States; enrollment included both treatment naïve and treatment-resistant patients as prior exposure to antidepressant medication was not a requirement for inclusion into the trial.
"The study found sTMS therapy to be significantly more effective than sham when administered as intended, supporting the hypothesis that low-field magnetic stimulation improves depressive symptoms," said Principal Investigator Andrew Leuchter, MD, Professor of Psychiatry and Director of the Neuromodulation Division in the Semel Institute at UCLA1. "Additional analyses found subjects who failed to benefit from or tolerate prior antidepressant treatment in the current episode were most likely to demonstrate significant benefit from sTMS therapy compared to sham."
When delivered accurately and consistently, antidepressant resistant/intolerant subjects treated with active sTMS therapy achieved clinical response at a rate of 34.2% compared to 8.3% of those treated with an inactive device.
In addition, NEST® showed an attractive safety and tolerability profile, with no significant differences seen between active and sham treatment in the rate or severity of adverse events. There were no device-related serious adverse events in this study.
"These promising results indicate that sTMS is a promising novel technology for the treatment of depression," said co-author Mark S. George, MD, Distinguished Professor of Psychiatry, Radiology and Neurology at the Medical University of South Carolina, and the Editor-in-Chief of Brain Stimulation. "This technology is revolutionary in two ways over the current FDA-approved forms of TMS. First, this device tunes the stimulation to the patient's own brain rhythms. By stimulating at each patient's individual resonant frequency, sTMS may be able to achieve therapeutic success using lower energy. Second, this device is safe, easy to use, and portable, which would allow use in a wide variety of treatment settings. sTMS may expand the options we have for treating serious depression."
"We are very pleased with the outcome of this trial and what it could mean for those with MDD, particularly those who have failed to achieve adequate improvement from prior antidepressant treatment," said Kate Rumrill, President and CEO of NeoSync. "This study is an important milestone for the company on the path to bring sTMS to the market."
###
Notes for Editors
The article details of the study are: Leuchter AF, Cook IA, Feifel D, et al. Synchronized Transcranial Magnetic Stimulation (sTMS) Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimulation 2015 http://dx.doi.org/10.1016/j.brs.2015.05.005
Article Information
1. Dr. Leuchter also serves as Medical Advisor for NeoSync.
Copies of study are available to credentialed journalists upon request.
About NEST® Technology
NEST® (NeoSync-EEG Synchronized TMS) delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions (5 days/wk) to gently adjust a depressed patient's brain toward a more normal state. Unique among TMS therapies, the synchronized TMS (sTMS) used by NEST® is personalized to a patient's intrinsic alpha frequency (IAF), as measured by the electroencephalogram (EEG). This design theoretically allows therapeutic stimulation using lower magnetic field energy, providing greater patient comfort during stimulation. The lowered energy requirements also allow NEST® to be much smaller and more portable than traditional TMS systems. The FDA has classified the NEST system as a Non-Significant risk (NSR) medical device, currently for investigational use only.
About NeoSync, Inc.
NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products designed to treat Major Depressive Disorder and other diseases of the Central Nervous System (e.g. Autism, Parkinson's disease, Anxiety, Post-Traumatic Stress Disorder, etc.). The Company is led by experienced medical device executives and entrepreneurs. Headquartered in Newton, MA, NeoSync is privately held.
About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. http://www.elsevier.com
Media contact
Natalie Hill-Krasniq
Brain Stimulation
n.hill-krasniqi@elsevier.com
Kate Rumrill
President and CEO
NeoSync
+1 781 373 1078
krumrill@neosync.com
Journal
Brain Stimulation